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ABSTRACT 
Background Alzheimer disease includes plaques consisting of aggregates of amyloid 
beta (Ap). AP is the product of abnormal cleavage of amyloid precursor protein (APP) by 
the secretases P-APP cleaving enzyme-I (BACEl), Presenilin-1 (PSENI) and disintegrin 
and metalloprotcinase-10 (ADAMlO). Recent studies postulate a correlation between 
amyloidogenic processing of APP and infection of neuronal cells by bacteria or viruses. 
Here we examine the ability of Herpes simplex virus type I (HSV-1) and Chlamydia 
pneumoniae (Cpn) to modify the expression of BACEI, PSENI, and ADAMI 0 in 
infected astrocytes. Knowing how these two pathogens might affect the 
neurodegenerative pathway to AP may give us insight into the etiology of Alzheimer 
disease. 
Methods Astrocytes were infected in vitro with Cpn and/or HSV-1. At 24 and 48 hours 
of infection, the expression of ADAMlO, BACEI and PSENl was quantified by RT2-
PCR. Data from singly or dually infected cells were compared to uninfected cells. Cpn 
and HSV-1 copy numbers were measured by qPCR from the same RNA samples. A 
potential effect of infection on AP processing was examined by immunofluorescent 
labeling of astrocytes. 
Results After 24 hours ofHSV-1 infection, cells had decreased expression of ADAMlO, 
BACEl & PSENl, which was significantly more extensive after 48 hours ofHSV-1 
infection. In contrast, in cells infected with Cpn for 48 hours, BACE 1 expression was 
significantly increased, whereas that of ADAMI 0 and PSENl was unchanged. 
Interestingly, concurrent infection with HSV-1 and Cpn lessened the reduction in gene 
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expression due to HSV-1 alone. Cpn cDNA copy numbers were significantly increased in 
the presence ofHSV-1. HSV-1 cDNA copy numbers were largely unchanged by the 
presence ofCpn, however, a decrease in HSV-1 cDNA copy number was detected ifCpn 
was added simultaneously with HSV-1. Immunofluorescent labeling revealed increased 
labeling of A~ in infected astrocytes relative to uninfected cells. 
Conclusions While HSV-1 infection may decrease host cell secretase gene expression, 
the presence of Cpn may modulate this effect. The ability of either pathogen alone to 
induce changes in the amyloidogenic pathway may be altered during active Cpn and 
HSV-1 coinfection. 
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INTRODUCTION 
1.1 Neurodegenerative Disease: Alzheimer disease 
Alzheimer disease (AD) is a common type of dementia seen in the elderly; it is 
characterized by initial loss of short-term memory progressing to loss of cognition 
function. By 2050 AD prevalence is predicted to triple from 2010 [ 1]. Also as the baby 
boomers age, the number of AD patients will dramatically increase. There are two 
general forms of AD, familial and sporadic. Familial AD, or early onset AD (EOAD), as 
its name implies, is dependent on genetics and usually affects a younger population, 
while the cause of sporadic AD, or late onset AD (LOAD), is unknown and it affects 
older patients. The majority of AD cases are LOAD, hence determining the mechanism 
and cause of this form of AD is gravely important. Furthermore, understanding potential 
triggers of LOAD may provide insight into how best to diagnose and treat this 
progressive neurodegenerative illness. 
1.2 Alzheimer disease pathophysiology 
The hallmarks of AD are neurofibrillary tangles (NFTs) and amyloid plaques [2]. 
The aggregates ofNFTs and amyloid plaques correlate with the loss of neurons in the 
amygdala and hippocampus, two critical locations for memory processing [3]. NFTs are 
composed of hyperphosphorylated tau proteins, which are normally used for stabilizing 
microtubules in neurons. When these proteins are hyperphosphorylated, they lose their 
solubility and tend to aggregate forming NFTs [ 4]. 
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Amyloid plaques are aggregates of a peptide called amyloid-beta (Ap). AP is 
derived from proteolytic processing of amyloid precursor protein (APP), a cellular 
transmembrane protein. APP is internalized through c!athrin/raft-mediated endocytosis 
and is processed by secretases in endosomes [5]. As illustrated in Figure I.I, there are 
two postulated pathways for the cleavage of APP: the non-amyloidogenic pathway and 
the amyloidogenic pathway [ 6]. 
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The non-amyloidogenic pathway involves an a-secretase named ADAMIO, which 
belongs to a disintegrin and metalloprotease family of proteases [7]. ADAMI 0 cleaves 
within the AP cleavage site, causing secretion of a soluble large N-terminal ectodomain 
named soluble APP a (sAPPa); the remaining portion of APP attached to the membrane 
is the carboxyl terminus end called C88 [8]. Then y-secretase, whose catalytic domain is 
named presenilin I (PSENI ), cleaves at amino acid residue C83 creating a nontoxic 
protein named P3 and an intracellular protein named APP intracellular domain fragment 
(AICD) [9, 10]. AICD is a known to activate promoters for neprilysin and glycogen 
synthase kinase 3P (gsk3P) [11]. 
The amyloidogenic pathway involves a P-secretase, P-site APP cleaving enzyme 
(BACE 1) that is usually found in endosomes [9]. BACE I cleaves APP within the lumen 
ofthe endosome, resulting in the secretion of soluble APP p (sAPPP) through exocytosis 
and a membrane bound carboxyl terminal fragment 99 amino acids long named C99. 
PSENl then cleaves C99 in the membrane of the endosome releasing AICD and various 
sized AP peptides, most commonly AP (J.40) or AP (1-42), depending on the exact cleavage 
site [9, 10, 12]. AP (1-42) is more prevalent in plaques due to its decreased solubility 
compared to AP (1-40), which enhances its capacity to aggregate [13]. This amyloidgenic 
pathway culminates in A~ being released extracellularly where it can aggregate to form 
the amyloid plaques seen in AD. 
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The left-sided pathway shown is the non-amyloidogenic pathway involving an a-secretase 
(ADAMI 0) and a.y-secretase (PSENI) leading to the production of soluble APP fragments. The 
right-sided pathway is the amyloidogenic pathway leading to the production of neurotoxic P-
amyloid through cleavage mediated by a P-secretase (BACEI) and PSENI. 
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1.3 Alzheimer's Disease and apoE 
A potential trigger for AD is linked to an apolipoprotein E gene ( apoE) isotype. 
This gene fimctions in both the central nervous system (CNS) and the vascular system as 
a lipid carrier. ApoE is predominantly produced by astrocytes and is essential for myelin 
sheath production and repair in mature neurons [14]. There are multiple different isotypes 
of apoE, with apoE allele type E4 (apoEE4) being associated with AD, atherosclerosis, 
and susceptibility to certain infections [15, 16]. The presence of this gene will increase 
the incidence and the onset of AD [ 17]. 
Research has shown that apoEE4 is involved with AP metabolism by influencing 
the aggregation and clearance of AP [15, 18]. APOEE4 has been shown to have a 
decelerated clearance of AP when compared to the other isotypes in vivo, however there 
is little impact in the rates of AP processing among the isotypes of apoE [19]. The 
mechanism of apoEE4 causing a decline in clearance could be due to the weaker binding 
of AP to apoEE4 than the other isotypes, thereby causing a lower rate of clearance. 
Degradation of AP occurs with neprilysin and insulin degrading enzyme (IDE); these 
enzymes are increased in the presence of apoE, however with apoEE4 there could be an 
inhibition or decrease of these enzymes causing AP accumulation [18]. Additionally, 
apoEE4 has been correlated with increased susceptibility to AP-induced oxidative damage 
[ 16]. Also, when compared to the different apoE isotypes, apoEE4 has been linked to a 
diminished immune defense mechanisms in the presence of bacteria and viruses [16]. 
Therefore the additive effects of decreased clearance of pathogens and AP causes 
APOEE4 allele to be known as a risk factor for AD. 
1.4 P-site APP cleaving enzyme 1 (BACEl) 
BACE 1 expression is prevalent in the nervous system, more commonly found in 
neurons compared to other cell types [20]. This protease goes through significant post-
transcriptional modifications, first synthesized as a zymogen where it is cleaved in the 
endoplasmic reticulum, following folding with cross linking at the catalytic domain [21]. 
BACEl is located in endosomes and trans-golgi network, however it needs to be 
internalized from the plasma membrane in order to cleave APP, and then degraded in 
lysosomes [22]. BACEl activity is optimal at an acidic pH and this secretase localizes to 
early endosomes where it encounters and cleaves APP [ 5]. Normally, a miniscule 
amount of APP is processed by BACEl however it has been shown in the presence of 
high concentration of intracellular cholesterol lead to an increased production of Ap, 
allowing the speculation that BACEl activity is heightened in a lipid rich environment 
[23]. Increase in apoEE4 or abnormalities oflipid production could influence the 
internalization or activity ofBACEl therefore causing the accumulation of Ap. 
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Since BACEl expression and activity is associated with AP accumulation, which 
is a key component of AD pathology, there is interest in using BACE I inhibitors as 
therapeutic agents in AD [20]. However, processing of various substrates by BACE 1 has 
been implicated in the regulation of axonal myelination, synaptic function, axon guidance 
and neurogenesis [21, 24]. Thus, because of the multiple functions ofBACEl in addition 
to APP processing, the use ofBACEl inhibitors to manage AD needs to be closely 
monitored [21, 24]. BACE I expression has been shown to increase dming hypoxia and 
oxidative stress [23], which can be caused by pathogens during chronic infections. 
Additionally, inflammation and metabolic stress can manipulate translation ofBACEl 
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[25]. Overall, BACEI is a prerequisite for A~ production and aggregation and potentially 
a key player in explaining how pathogens, such as HSV-1 and Cpn, can play a role in the 
etiology of AD. 
1.5 Presenilin (PSEN) 
Mutations in presenilin 1 (PSENl ), presenilin 2 (PSEN2) and APP genes are the 
most common cause of familial AD [26]. PSENl and PSEN2 are the catalytic domains of 
y secretase, a multi-subunit protein complex composed of PSENl or PSEN2, nicastrin, 
anterior pharynx -1, and PSENl enhancer-2, all of which are required for enzymatic 
activity [27]. Interestingly, PSENl can function as a regulator in the maturation of 
BACEl [9]. As with BACEl, there are multiple substrates that can be cleaved by y-
secretases in addition to APP, an important one being Notch, a signaling protein involved 
in cell differentiation. Disruption of Notch signaling has been associated not only with 
abnormalities in development, but also with some cancers and dysregulated T and B 
lymphocyte differentiation [28, 29]. Therefore inhibition of PSENI activity to minimize 
production of A~ could potentially have adverse consequences unless inhibition was 
specific for APP processing. 
1.6 A Disintegrin and Metalloprotease-10 (ADAMlO) 
ADAMlO is an important member ofa disintegrin and metalloprotease family of 
proteins. These proteases, along with BACE proteases, are called "sheddases" because 
they cleave membrane-bound substrates to release an ectodomain. The C-terminal 
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domain may subsequently undergo additional proteolytic processing, referred to as 
regulated intramembrane proteolysis (RIP), by proteases such as y-secretases [30]. This is 
the process involved in the non-amyloidgenic pathway of APP processing described 
above, which consists of sequential ADAMI 0 and y-secretase cleavage events. While 
ADAMIO activity does not cause of the production of toxic AP fragments, a decrease in 
ADAMI 0 activity can lead to an accumulation of Ap. As with the P- and y-secretases, 
ADAMlO can cleave many substrates, including synaptic proteins. Therefore loss of 
ADAMI 0 activity disrnpts the structure and function of synapses. In addition, ADAMI 0 
activity releases the Notch ectodomain, allowing y-secretase to activate Notch signaling 
through RIP [8, 30]. Thus both ADAMlO and PSENI activity are required for normal 
brain development and function mediated by Notch signaling pathways. 
1.7 Pathogens and Neurodegenerative Disease 
Recent studies on AD focus on how inflanunation can increase the amyloidogenic 
pathway. Studies have shown that infectious burden attributed to multiple pathogens 
correlates with significantly elevated levels of inflanunatory cytokines and serum Ap, as 
well as with AD and higher levels of impaired cognition [3 I]. Chronic activation of the 
immune system can cause dysregulation of the blood brain barrier, allowing 
autoantibodies to enter the CNS and activate glial cells thereby causing more disruption 
in the brain [32]. It has been postulated that infectious agents, such as Chlamydia 
pneumoniae (Cpn) and Herpes simplex virus type I (HSV-1), play a role in the etiology 
of AD [33, 34]. In autopsied brains of AD patients, DNA and protein specific for Cpn 
were detected where AD pathology is observed in the brain [35, 36]. Other studies have 
shown an increase in the production of AP in the brains of mice infected with HSV-1 
[37], as well as HSV-1 DNA associated with amyloid plaques [38]. Therefore, 
understanding the mechanisms of Cpn and HSV-1 on the amlyoidgenic pathway will 
bring insight on the pathology of AD. 
1.8 Chlamydia pneumoniae 
Chlamydia pneumoniae ( Cpn) is an obligate intracellular bacterium typically 
considered a respiratory pathogen causing chronic puhnonary infections, but also 
postulated to play a role in atherosclerosis [39, 40]. In addition, this bacterium has been 
detected in the central nervous system (CNS) of patients with AD [ 41 ]; an investigation 
by Macintyre et al. [ 42] suggests that Cpn can enter the CNS by transmigrating through 
brain endothelial cells within infected monocytes. Cpn reside in astrocytes and microglia 
cells in the CNS [ 17]. 
Cpn has a biphasic life cycle (Figure 1.2) consisting of an elementary body (EB) 
that is infectious, though, metabolically inactive, and a reticulate body (RB) that is 
noninfectious but metabolically active [43]. EBs are typically found extracellularly and 
taken into the host cell through endocytosis after binding to heparin sulfate receptors on 
the host cell [44]. Once in the cell's endosome, EBs convert into RBs that will then 
multiply through binary fission. Using nutrients and energy provided by the host cell, 
RBs produce EBs that are released through endocytosis or cell lysis. When the cell is 
stressed, Cpn may go into persistence, whereby RBs form an aberrant body [ 4 3]. In this 
alternate state, Cpn conversion from RB to EB ceases and metabolism is reduced, though 
DNA continues to replicate. 
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Infectious burden from Cpn has been shown with increased serum levels of AP in 
AD and healthy control patients [31]. This could be due to the theory that AP has 
antimicrobial properties therefore accumulation of AP is a defense mechanism towards 
Cpn [ 45]. Also, the increased AD risk associated with the apoEE4 allele could be linked 
to Cpn by the observation that apoEs4 favors the attachment of EB to host cells compared 
to other apoE isotypes, thereby potentially augmenting Cpn infection [ 46]. 
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The EB form enters the host cell and is converted to an RB, proceeding to multiply and 
eventually produce EBs. Once the host cell lysis occurs, EBs are released to start infecting other 
host cells. When certain stressors are present Cpn can enter a phase of persistence. Schematic 
modified from [43] 
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1.9 Herpes Simplex Virus Type 1 
HSV-1 is a DNA virus that belongs to the Alphaherpesvirinae subfamily; it is 
ubiquitous and known to cause labial sores as well as sporadic cases of viral encephalitis. 
HSV-1 can become latent and persist life-long in the trigeminal ganglion with periodic 
episodes of reactivation of productive infection. The spread of HSV-1 occurs following 
contact with a person who is productively infected and shedding the virus. 
Primary infection is limited to about 10 to 14 days depending on the host's 
immune system [47]. Envelope glycoproteins B, C, and D ofHSV-1 initiate entry into a 
host cell by binding to host cell receptors such as heparin sulfate and nectin [ 48, 49]. 
After the virus has entered into the host cell through receptor-mediated endocytosis, the 
viral capsid will migrate to the nucleus and release its DNA across the nuclear 
membrane. As HSV-1 replicates, it expresses proteins that promote transcription and 
translation of viral genes and shut dowu host protein synthesis. Following both protein 
synthesis of viral structural proteins and replication of the viral genome, progeny virions 
will assemble, pass through the nuclear membrane, bud into the trans-golgi network 
where they acquire envelope glycoproteins, and finally exit the cell through exocytosis 
[ 50]. The virus will utilize actin as a mechanism to travel and grow throughout the host 
cell. HSV-1 is known to use microtubules for transportation to the nucleus in order to 
replicate [51, 52]. 
While a productive HSV-1 infection takes place in epithelial cells, viral particles 
travel via retrograde axonal transport to the trigerninal ganglion where the virus 
establishes latency. Once the virus is reactivated it will travel back dowu to the epithelial 
cell. He1pes simplex encephalitis (HSE) can occur if there is a chronic infection of HSV-
1 mainly infecting the temporal lobe. The vims in its latent phase was detected in the 
hippocampus and temporal lobe in AD patients [53]. 
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Studies have speculated how HSV-1 can play a role in AD pathology by 
influencing the production of tau phosphorylation via augmenting kinases such as gsk3p 
or attenuating phosphatases [ 54]. Also, viral proteins of HSV-1 are homologous to 
proteins of Ap, therefore producing auto-antibodies that could have an effect on Ap [32]. 
Other ways that HSV-1 may have a role in AD is via apoEs4. It has been shown that 
HSV-1 is a risk factor for AD in individuals that carry the apoEs4 allele [55-57] and that 
in an animal model, mice expressing apoEs4 develop a higher HSV-1 load in their brain 
than mice expressing apo&3 [58]. This could be because heparin sulfate proteoglycan is 
used by apoE and HSV-1 for entry into cells and perhaps HSV-1 outcompetes apoEs4 for 
binding to the receptor, increasing the chances ofHSV-1 infecting host cells [ 56]. 
Moreover, Burgos et al. [59] speculated that HSV-1 could be using apoE as a mode of 
transportation for hematogenous routes of infections. Bullido et al. report that apoEs4 
carriers with polymorphisms of the transporter associated with antigen presentation 
(TAP) are at an increased risk of AD and speculate that these changes could affect the 
host immune response to HSV-1 infection [60]. This idea is supported by an investigation 
indicating that the HSV-1 protein that inhibits TAP activity influences neuroinvasiveness 
of the virus [61]. Associations between HSV-1 and known risk factors for AD, namely 
apoEs4 and TAP, increase the likelihood that HSV-1 plays a role in the etiology or 
pathology of AD. 
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1.10 Coinfection of Chlamydia pneumoniae and Herpes simplex virns type 1 
Infectious burden from pathogens can serve as a risk factor for AD. Overall there 
are multiple investigations published showing a possible role for Cpn and HSV-1, 
individually, in triggering events that lead to AD [33, 34]. Both pathogens are common in 
the elderly and once infected an individual can remain infected indefinitely, therefore 
there is a high likelihood of having concurrent infections ofHSV-1 and Cpn. It is known 
that both pathogens find entry into the host cells by binding to heparin sulfate 
proteoglycans, [ 44, 48] therefore both pathogens may have an effect on each other. 
Previous studies in our laboratory have suggested that in terms of replication, HSV-1 can 
have an effect on Cpn and vice versa. This investigation addresses whether the two 
pathogens affect the processing of APP, perhaps by altering the activity of the secretases 
involved in APP cleavage, and how dual infections with Cpn and HSV-1 may modify the 
effects observed with a single pathogen. 
1.11 Specific Aims 
There are two primary aims of this project. First is to analyze changes in 
expression ofBACEl, PSENI, and ADAMIO genes using RT2-PCR on cDNA derived 
from astrocytes infected with Chlamydia pneumoniae and/or HSV-1 for 24 or 48 hours. 
Gaining knowledge on how these pathogens affect astrocytes will give us insight on how 
these pathogens are involved with neurodegenerative diseases. A second aim is to better 
understand how Chlamydia pneumoniae and HSV-1 affect the life cycle of one another in 
dually infected cells. 
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1.12 Hypothesis 
We postulated that dual infections of astrocytes by HSV-1 and Chlamydia 
pneumoniae alters gene expression of secretase genes to a greater extent than that seen 
with either pathogen alone, resulting in increased processing of amyloid precursor protein 
into Ap. Also, we hypothesized that replication ofHSV-1 would affect Chlamydia 
pneumoniae replication to a greater extent than vice versa in dually infected cells. 
METHODS 
2.1 Cell lines 
STGGl, a human astrocyte cell line (ATCC; CRL-1718), was maintained in 
RPMI-1640 (ATCC) containing 10% heat inactivated fetal bovine serum (RPMI-FBS) 
(Coming Life Sciences) and cultured at 37°C in 5% COi. Cells destined for infection 
were passaged at approximately 85% confluency. 
15 
Vero cells (ATCC;CCL-81), an African green monkey kidney cell line, were used 
for HSV-1 plaque assays. Vero cells are commonly used for measuring viral replication. 
They were propagated in Eagle's minimum essential media (EMEM) with 10% HI-PBS 
at 37°C in 5% C02. 
2.2 Infection of astrocytes 
STTG 1 monolayers were grown for 2 days in 12-well plates seeded at 5xl 05 per 
mL ofRPMI-FBS, at which point the mean cell count from 2 wells was determined using 
the Countess Automated Cell Counter protocol (lnvitrogen). Cells were infected with 
Cpn (respiratory strain AR39; ATCC 53592) and/or HSV-1 (Macintyre strain; ATCC; 
VR-539D) at a multiplicity of infection of0.5 and 0.02, respectively. The ATCC Cpn 
stock was considered to have 5 x 104 infectious units per 20 µL, while the HSV-1 stock 
contained 8 x 105 plaque forming units per mL as determined by plaque assay. To 
inoculate cells, media was removed from the wells and the appropriate amount of Cpn 
and/or HSV-1 in RPMI-FBS was added in a final volume of200 µL. After a 1 hour 
incubation period at 3 7°C to allow the pathogens to attach to the astrocytes, the volume 
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was adjusted to 1 mL and cells were incubated for a total of24 or 48 hours. Uninfected 
cells were treated similarly and harvested at 24 and 48 hours post inoculation (hpi). For 
coinfected monolayers, Cpn and HSV-1 were either added simultaneously or infections 
were staggered. The second pathogen was added to staggered coinfections at 24 hpi by 
removing-800 mL RPMl-FBS and storing it at 37°C. The second pathogen was added to 
the remaining media on the cell mono layer (200 µL final volume) and incubated at 3 7°C 
for an hour, then the 800 mL of stored media was placed back into their designated wells 
for the remaining 24 hours (Figure 2.1 ). 
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Experimental Design for astrocyte coinfections 
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Figure 2.1. Experimental Design for astrocyte coinfections. 
A depiction of the times of HSV-1 and/or Cpn infection for the eight experimental groups. 
Uninfected cells were harvested at 24 and 48 hpi. Each of the uninfected and infected samples 
were obtained in triplicate for each coinfection. 
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2.3 Generating RNA lysates 
RNA was extracted from astrocytes using Qiagen's RNeasy Kit (Qiagen) 
following the manufacturers recommended protocol. The wells were first washed with I 
mL of Hank's Balanced Salt Solution (HBSS) without calcium and magnesium, then 300 
µL of the RL T lysis buffer from the RNA isolation kit was added to the wells. The 
samples were stored at -80°C until further extraction. Once the lysates were thawed, 
they were placed overtop the Qiashredder colunm (Qiagen) and centrifuged at 8,000 xg 
for 2 minutes. The flow-through was mixed with 350 µL of70% ethanol and placed on 
an RN easy spin colunm. Additional steps were taken to ensure complete DNA removal 
using the RNase-Free DNase Kit (Qiagen) and its recommended protocol. After the 
completion of the DNase protocol, Qiagen's protocol for the "Purification of total RNA 
from animal cells using spin teclmology'' was followed; RNA was eluted into 30 µL of 
RNase-free water. The optical density was measured for each sample to determine the 
concentration of RNA and its purification using the Thermo Scientific's NanoDrop 2000c 
UV-Vis Spectrophotometer at 260/.,, 280/.,, and 230/.,. Samples were then stored in -80°C 
until needed. 
2.4 Generating cDNA from mRNA 
RNA (IOOng) was converted into cDNA using Ambion's RETROscript kit (Life 
Technologies). In a 0.2 mL sterile PCR tube, IOOng of RNA was combined with 3 µL of 
random decamers and brought up to 18 µL using nuclease-free water. The mixture was 
spun for 5 seconds at 11,000 rpm in a Spectrafuge l 6M microcentrifuge (Denville 
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Scientific) after being flicked to ensure proper mixing. Samples were placed in the 
Techne TC 3000G Thermocycler (Fisher Scientific) and denatured at 80°C for 3 minutes, 
then held on ice before addition of the reverse transcriptase master mix. The master mix 
contained 3 µL of !Ox RT buffer, 6 µL of dNTP mix, 0.75 µL ofRNase inhibitor, 0.75 µL 
ofMMLV Reverse Transcriptase and 1.5 µL of nuclease free water per RNA sample; 12 
µL of this master mix was added to each RNA/random primer sample for a total volume 
of 30 µL. The mixture was then placed in the Techne TC 3000G Thermocycler and 
incubated at 43°C for I hour, followed by 92°C for 10 minutes to inactivate the reverse 
transcriptase. Samples were then stored at -20°C. 
2.5 RT2-PCR for ADAMlO, BACE1, PSEN1, and actin gene expression 
Gene expression of ADAMIO, BACEI, PSENI and actin was quantified using 
Taqman gene expression system (Applied Biosystems) in a multiplex set up with 18s 
rRNA as endogenous control. A primer master mix was assembled using I 0 µL of 2x 
Taqman gene expression master mix, I µL of l 8s rRNA primer limiting primer, and I µL 
of the experimental primer (ADAMI 0, BACEI, PSENI or actin) per well. All primers 
were obtained from Thermofisher. Thirty microliters of the sample cDNA was combined 
with 75 µL of nuclease free water to make a sample master mix with a total volume of 
I 05 µL; each master mix was pipetted up and down to ensure a homogenous suspension. 
Twenty-five microliters of the sample master mix was combined with 37 µL of the 
designated primer master mix. This final mixture was mixed by flicking and was 
centrifuged for 5 seconds at 11,000 rpm in a Spectrafuge 16M microcentrifuge (Denville 
Scientific). A total of 20 µL of the final mixture was pipetted into the designated well in 
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triplicate. Once all the samples were loaded into 96-well plate (Thermofisher), they were 
sealed and capped with cap strips (Thermofisher). RT-PCR was performed using an 
Applied.Biosystems StepOne Plus RT-PCR instrument. The cycling protocol is depicted 
in Table 2.1 for 40 cycles. The Thermofisher Cloud Software 
(https://apps.thermofisher.com/apps/spa/#/dashboard; Relative RQ Application) was used 
to analyze the amplification data received from the StepOne Plus. 
Table 2.1. Cycling Protocol for RT-PCR 
Holding Stage 95°C for 10 minutes 
95°C for 15 seconds 
Cycling Stage 
60°C for I minute 
2.6 Quantification of HSV-1 and Chlamydia pneumoniae copy numbers 
HSV-1 and Cpn copy numbers were measured in cDNA samples by RT-PCR 
using Cpn- and HSV-1-specific primers from Primer Design (Gensig). A primer master 
mix was assembled using 40 µL Taqman gene expression master mix, 4 µL ofHSV-1 or 
Cpn primer and 22 µL of nuclease water, which generates 6 µL extra reaction mixture to 
account for pipette variability. The primer master mix was pipetted up and down to and 
then split into 0.2mL sterile PCR tubes. Twenty microliters of cDNA generated from 
100 ng of RNA as described above was added to the PCR tube containing the primer 
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master mix and homogenized again by pipetting up and down. Twenty micro liters of the 
final mixture was then pipetted into designated wells in quadruplicate, with each well 
containing cDNA derived from 25 ng of RNA. Standard curves for determining Cpn and 
HSV-1 copy number were set up similarly to experimental samples, substituting 5 
µUwell diluted standards provided by Gensig for sample cDNA. Samples and standards 
were amplified as described above except that during the cycling stage the plates was 
held at 95°C for 10 seconds instead of 15 seconds; data was analyzed using the 
Thermofisher Cloud Software (https://apps. thermofisher.corn/apps/spa/#/dashboard; 
Standard Curve Application). 
2.7 Immunofluorescence 
Astrocytes were infected in 12-well plates containing glass coverslips (GG-12-
1.5-pre, Neuvitro). Once the infection was complete, coverslips were placed in a new 12-
well plate with 1 mL ofHBSS in each well. HBSS was removed and 500 µL of 
Cytofix/Cytoperm Buffer (Invitrogen) added for 30 minutes. Samples were washed with 
1 mL phosphate-buffered saline (PBS) twice. Thirty minutes of incubation at room 
temperature (25°C) with 1 mL of Ix Permwash (Thermofisher) was used to block the 
samples. Cells were then incubated at 4 °C overnight with primary antibodies diluted to 
the desired concentration (Table 2.2) with 1 x Permwash. The appropriate secondary 
antibody, diluted in 1 x Permwash, was added to the samples maintained above a 3 7°C 
water bath for 2 hours. Coverslips were inverted and mounted on microscope slides with 
10 µL offlurogel II mounting media containing DAPI (17985-50, Electron Microscopy 
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Sciences). Images were taken either on an epi-fluorescent scope (Nikon Eclipse 90i) or 
on Olympus FVl 000 Confocal microscope. 
Table 2.2. Primary and secondary antibodies used for immunofluorescence 
Primary Antibody Secondary Antibody 
T96 594 Anti-mouse 
Thermofisher, 1:1000 Molecular 1:500 
MAl-19267 Probe, A-11029 
HSV-1 
FITC conjugated 
Fitzgerald, 1:1000 -
60C-CR2124RF 
FITC conjugated 
Cpn Fitzgerald, 1:200 -
61C75A 
6El0 555 Anti-mouse 
Amyloid BioLegend, 1:200 Molecular 1:200 
SIG-39320 Probe, A32727 
AP42 594 Anti-rabbit 
Amyloid p 1-42 Synaptic Systems, 1:200 Molecular 1:200 
218-703 Probe, A-11037 
Poly8119 488 Anti-rabbit 
AICD Bio Legend, 1:1000 Molecular 1:1000 
SIG-39148 Probe, A-11034 
BACEl 488 Anti-rabbit 
BACEl Abeam, 1:1000 Molecular 1:500 
Abl0716 . Probe, A-11034 
2.8 Statistical analysis 
The Thermofisher Cloud Software for analyzing gene expression 
(https://www.thermofisher.com/us/en/home/digital-science.html) utilizes a two-tailed 
Student's T-test using delta CT values obtained during RT-PCR amplification to 
determine the significance between the expressions of host genes in different samples. 
The significance between pathogen copy numbers was determined by an analysis of 
variance (ANOVA) using the Holm-Sidak method for pairwise multiple comparison. P 
values~ 0.05 were considered significant. 
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RESULTS 
3.1 Changes in host cell gene expression in uninfected samples over time 
RT2- PCR was used to determine whether there is a change in expression of 
ADAMI, BACEl, PSENl and actin following dual and single infections in astrocytes; 
18s rRNA was used as the endogenous control. Potential changes in gene expression 
were compared to expression in uninfected samples at 24 hours and 48 hours post 
infection (hpi). Interestingly, the host gene expression of all 4 genes in uninfected 
astrocytes was reduced at 48 hours compared to that at 24 hours (Figure 3.1). BACEl and 
actin gene expression in uninfected astrocytes was significantly reduced at 48 hours (p-
values = 0.005 and 0.05, respectively). Consequently, expression of host genes at 24 hpi 
was measured relative to 24 hour uninfected samples while that at 48 hpi was measured 
relative to 48 hour uninfected samples. 
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Figure 3.L Expression of ADAMlO, BACEl, PSENl, and actin by astrocytes in uninfected 
samples at 24 hours and 48 hours. 
Equal volumes of cDNA generated from reverse transcription of equal amounts of RNA derived 
from uninfected astrocytes were amplified by quantitative PCR using 18s rRNA as the 
endogenous control to normalize samples. Shown is the mean relative gene expression derived 
from 3 separate infections performed in triplicate (n=9) and expressed relative to 24 hour 
uninfected cells; error bars represent the 95% confidence interval. 
• BACEl (p = 0.005) and actin (p = 0.05) expression was significantly reduced in 48 hour 
uninfected cells as compared to that of 24 hour uninfected cells. 
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3.2 Changes in host gene expression at 24 hours post infection 
Relative expression of ADAMl, BACEl, PSENl, and actin following 24 hours of 
single or dual infection with HSV-1 and/or Cpn is shown in Figure 3.2. Reduction in 
expression of ADAM 10 and BACEl in astrocytes infected with HSV-1 for 24 hours 
approached significance with p-values of 0.06 and 0.07, respectively, while the reduction 
in expression of PSENl in these samples was significant (p = 0.02). Although there was 
a reduction in ADAMIO, BACEl, and PSENl mRNA levels in astrocytes infected with 
HSV-1for24 hours, there was no significant change in actin rnRNA levels following 24 
hours of infection with HSV-1. Astrocytes infected with Cpn alone or a 24 hour 
coinfection with simultaneous inoculation of HSV-1 and Cpn (HSV-1/Cpn 24/24 hpi), 
showed no significance difference in expression of all 4 genes compared to uninfected 
samples. 
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Figure 3.2. Expression of ADAMlO, BACEl, PSENl and actin by astrocytes in the presence 
or absence of HSV-1 and/or Chlamydia pneumoniae at 24 hours post infection. 
Equal volumes of cDNA generated from reverse transcription of equal amounts of RNA derived 
from infected and uninfected astrocytes were amplified by quantitative PCR using 18s rRNA as 
the endogenous control to normalize samples. Shown is the mean relative gene expression 
derived from 3 separate infections performed in triplicate (n=9) and expressed relative to 24 hour 
uninfected cells; error bars represent the 95% confidence interval. 
* Difference in gene expression in samples of 24 hour HSV-1 infected cells relative to 24 hour 
uninfected cells approached significance for ADAMlO (p = 0.06) and BACEl (p = 0.07). 
**Gene expression of PSENl in 24 hour HSV-1 infected cells was significantly reduced 
compared to that of24 hour uninfected cells (p = 0.02). 
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3.3 Changes in host gene expression at 48 hours post infection 
Relative expression of ADAMl, BACEl, PSENl, and actin following 48 hours of 
single or dual infection with HSV-1 and/or Cpn is shown in Figure 3.3. In addition to 
simultaneous inoculation ofHSV-1 and Cpn (HSV-1/Cpn 48/48 hpi), coinfections were 
also staggered so that cells were inoculated with the second pathogen at 24 hpi (HSV-
1/Cpn 24/48 hpi and HSV-1/Cpn 48/24 hpi), which would give the first pathogen time to 
establish an infection before addition of the second pathogen. All cells infected with 
HSV-1for48 hours showed a dramatic reduction in gene expression of ADAMlO, 
BACE l, PSENl, and actin relative to that of uninfected cells. When comparing 48 hour 
infections with HSV-1 alone to 48 hour simultaneous dual infections with HSV-1 and 
Cpn (HSV-1/Cpn 48/48 hpi), the coinfection showed an increase in gene expression in all 
4 genes with p-values <0.01. 
Astrocytes infected with Cpn alone for 48 hours did not show any changes in gene 
expression when compared to uninfected cells except for BACE 1, which was 
significantly increased (p-value = 0.02). Gene expression observed in staggered 
infections was dependent upon whichever pathogen was present for 48 hours; the 
addition of the second pathogen at 24 hpi had little effect on ADAMI, BACEl, PSENl, 
or actin gene expression with the exception ofBACEl expression in HSV-1/Cpn 24/48 
hpi samples. In these samples, the increase in BACEl expression seen at 48 hpi with Cpn 
was not observed when HSV-1 was added 24 hours after inoculation with Cpn. 
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Figure 3.3. Expression of ADAMlO, BACEl, PSENl and actin by astrocytes in the presence 
or absence ofHSV-1 and/or Chlamydia pneumoniae at 48 hours post infection. 
Equal volumes of cDNA generated from reverse transcription of equal amounts of RNA derived 
from infected and uninfected astrocytes were amplified by quantitative PCR using l 8s rRNA as 
the endogenous control to normalize samples. Shown is the mean relative gene expression 
derived from 3 separate infections performed in triplicate (n=9) and expressed relative to 48 hour 
uninfected cells; error bars represent the 95% confidence interval. 
*Gene expression in cells infected simultaneously for 48 hours with HSV-1 and Cpn (HSV-1/Cpn 
48/48 hpi) was significantly greater than that of cells infected for 48 hours with HSV-1 alone (p 
<0.01). 
** BACEl gene expression in 48 hour Cpn-infected cells was significantly increased relative to 
that of 48 hour uninfected cells (p = 0.02). 
***The reduction in actin gene expression between cells dually infected with HSV-1 for 24 
hours and Cpn for 48 hrs (HSV-1/Cpn 24/48 hpi) relative to 48 hour uninfected cells approached 
significance (p = 0.06). 
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3.4 Quantification of HSV-1 and Chlamydia pneumoniae copy numbers 
To assess whether HSV-1 can intenupt the life cycle of Cpn and if Cpn can affect 
HSV-1 replication, RT2-PCR was used to quantifyHSV-1 and Cpn copy numbers from 
cDNA. As would be expected, the infectious burden was substantially higher at 48 hours 
of infection compared to 24 hours of infection in astrocytes infected with HSV-1 (Figure 
3.4). However, a significant decrease in HSV-1 copy number was observed in cells 
simultaneously coinfected with HSV-1 and Cpn for 24 hours (HSV-1/Cpn 24/24 hpi) 
compared to cells infected with HSV-1 alone for 24 hours. This can also be said when 
compared to staggered coinfections where cells were initially infected with Cpn, then 
inoculated with HSV-1 at 24 hpi (HSV-1/Cpn 24/48 hpi). On the other hand, following 
dual infections where HSV-1 was present for 48 hours and Cpn for either 48 (HSV/Cpn 
48/48 hpi) or 24 (HSV-1/Cpn 48/24 hpi) hours, HSV-1 copy numbers were similar to that 
derived from 48 hour HSV-1 infections. 
As seen in Figure 3.5, astrocytes infected with Cpn alone, had a higher infectious 
burden at 24 hpi than 48 hpi. Interestingly, when comparing single and dual infections, 
the presence of HSV-1 was associated with an increase in Cpn copy number relative to 
that measured in cells infected with Cpn alone. 
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Figure 3 .4. HSV-1 copy number quantified in astrocytes in the presence and absence of 
Chlamydia pneumoniae. 
HSV-1 copy numbers were measured in cDNA derived from 3 infections performed in triplicate 
(n=9); error bars represent the standard error of the mean. 
* All 48 hour single and dual HSV-1 infected monolayers had significantly higher copy numbers 
relative to those of24 hour single and dual infections (p<0.001), however copy numbers from all 
HSV-1 48 hour monolayers were not different from each other. 
** Copy numbers from cells dually infected with HSV-1 and Cpn for 24 hours (HSV-1/Cpn 
24/24 hpi) were significantly reduced relative to that observed in both HSV-1 24 hour single 
infections (p = 0.007) and in dually infected cells exposed to HSV-1 for 24 hours and Cpn for 48 
hours (HSV-1/Cpn 24/48 hpi; p = 0.012). 
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Figure 3.5. Chlamydia pneumoniae copy number quantified in astrocytes in the presence and 
absence of HSV- L 
Cpn copy numbers were measured in cDNA derived from 3 infections performed in triplicate 
(n=9); error bars represent the standard error of the mean. 
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* Cpn copy numbers from monolayers infected with Cpn for 24 hours were significantly different 
from those of cells infected simultaneously with HSV-1 and Cpn for 24 hours (HSV-1/Cpn 24124 
hpi; p<0.001) and from dually infected cells exposed to Cpn for 24 hours and HSV-1 for 48 hours 
(HSV-1/Cpn 48124 hpi; p = 0.014) samples. 
** Copy numbers from monolayers infected with Cpn for 48 hours were significantly different 
from those of cells simultaneously infected with Cpn and HSV-1for48 hours (HSV-1/Cpn 48148 
hpi; p = 0.009) and staggered coinfections where cells were exposed to Cpn for 48 hours and 
HSV-1 for 24 hours (HSV-1/Cpn 24148 hpi; p = 0.01 ). 
3.5 Qualitative assessment of Chlamydia pneumoniae and HSV-1 infection of 
astrocytes 
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For further analysis of how Cpn and HSV-1 can affect each other's infectious 
processes, as well as the cells that they infect, a qualitative approach was taken by 
immunolabeling HSV-1 and Cpn in infected astrocyte monolayers. Immunofluorescence 
revealed that an astrocyte can be infected with Cpn and HSV-1 simultaneously (Figure 
3.6). It is common for HSV-1 infected astrocytes to become distorted and have a more 
rounded nucleus and to form syncytia, which are large multinucleated cells resulting from 
virus-induced cell-to-cell fusion. Syncytia are present in monolayers infected for 48 hour 
with HSV-1, and Cpn labeling was observed within the syncytia, indicating that it is 
possible for Cpn to infect cells that exhibit cytopathology consistent with viral infections. 
3.6 Qualitative assessment of Aj3 infected and uninfected astrocytes 
Immunofluorescence labeling was used to qualitatively assess changes in the 
protein levels of amyloid in infected astrocytes at 24 and 48 bpi. An antibody reactive to 
Aj3 residue 1-16 (6EIO) revealed an increase in the protein level of Aj3 in both Cpn- and 
HSV-1-infected cells relative to uninfected cells (Figures 3.7 and 3.8, respectively). 
When comparing 24 and 48 hour Cpn infections, it is difficult to determine if a prolonged 
infection with Cpn correlates with increased amounts of Aj3. Immunofluorescent 
labeling of 24 hour HSV-1 and Cpn dually infected cells revealed more intense labeling 
for amyloid compared to uninfected cells, regardless of whether or not the astrocytes 
were part of syncytia. 
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Figure 3.6. Immunofluorescent labeling of Chlamydia pneumoniae and HSV-1 in uninfected 
and dually infected astrocytes. 
Infections included 24 and 48-hour simultaneous inoculation with Cpn, and HSV-1. Cells were 
labeled for Cpn (green) and HSV-1 (red); nuclei were labeled with dapi (blue). 
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Figure 3.7. Jmmunofluorescent labeling of AJ3 and Chlamydia pneumoniae in uninfected and 
infected astrocytes. 
Infection included 24 and 48 hour single infections with Cpn, as well as 24 hour simultaneous 
dual infections with Cpn and HSV-1. Cells were labeled for Cpn (green) aod amyloid (red); 
nuclei were labeled with dapi (blue). 
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Figure 3.8. hnmunofluorescent labeling of Ai3 and HSV-1 in uninfected and infected 
astrocytes. 
Infection included 24-hour single infections with HSV-1, as well as 24-hour simultaneous dual 
infections with HSV-1 and Cpn. Cells were labeled for HSV-1 (green) and amyloid (red); nuclei 
were labeled with dapi (blue). 
37 
DISCUSSION 
4.1 Changes in astrocyte gene expression over time 
When comparing uninfected astrocytes at 24 and 48 hours, it was interesting to 
note that there was reduced gene expression in all four genes at 48 hours post-infection 
(hpi), which was statistically significant for both BACE 1 and actin mRNA. This 
difference in host gene expression over time may reflect changes in cellular growth rate, 
or other cellular processes, that occurs as the monolayers approach confluency. 
Therefore, it was necessary when assessing relative gene expression of infected cells that 
the comparison was made to the appropriate uninfected time point. 
4.2 Regulated intramembrane proteolysis mediated by a-, P-, and y-secretases 
The processing of APP via both the amyloidgenic and non amyloidgenic 
pathways are examples of regulated intramembrane proteolysis, or RIP [29]. In RIP, the 
a- or P-secretases initially cleave and release the ectodomain of a transmembrane protein. 
The y-secretases further cleave the membrane-associated C-terminal fragment, which can 
trigger activation or deactivation of different cell signaling processing, depending on the 
transmembrane protein that is being processed. For example, y-secretase cleavage of the 
C-terminal fragment of APP following initial ADAMI 0 and particularly BACEl 
cleavage releases AICD that returns to the nucleus to modulate gene transcription [ 62, 
63]. An additional important cell-signaling pathway that is activated by the process of 
RIP and mediated by ADAMlO & y-secretase is that of Notch. Notch signaling is 
involved in many cellular processes including proliferation, differentiation and cell death 
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[64]. Therefore, changes in expression of these secrctase genes can potentially contribute 
to CNS pathology through different cellular pathways, not just the amyloidgenic 
pathway. The diminished ADAMIO and PSENl gene expression observed in the 
presence of HSV-1 might disrupt cellular signaling pathways by disrupting Notch 
signaling, which could contribute to HSY-I-mediated cytopathology independently of 
effects of HSV-1 on APP processing. 
4.3 Manipulation of astrocyte gene expression in the presence of Herpes simplex 
virus type 1 
It is common for gene expression of the host cell to diminish in the presence of a 
viral infection. Since HSV-1 manipulates gene expression it was necessary to find a gene 
that remains stable during viral infection of astrocytes to use as a housekeeping gene for 
quantitative RT-PCR. Earlier work from our lab determined that the cycle thresholds 
observed during amplification of cDNA derived from HSV-1-infected astrocytes using 
actin- and GAPDH-specific primers change over time, while that observed using 18s 
rRNA-specific primers do not. Therefore, when comparing gene expression in uninfected 
and infected cells by quantitative RT2-PCR, 18s rRNA was used as the reference gene to 
normalize gene expression to cDNA levels. 
In astrocytes infected with HSV-1 for 24 hours, there was a reduction in 
ADAMlO, BACEl, and PSENI gene expression when compared to uninfected astrocytes 
at 24 hpi. Whereas gene expression of the secretase genes was downregulated, that of 
actin mRNA remained the same during a 24 hour infection suggesting that the decrease in 
secretase gene expression was not just due to generalized suppression of host 
transcription in the present of the virus. It is possible that actin gene expression is 
conserved at early times post infection because HSV-1 utilizes actin to help enter target 
cells and initiate viral replication [ 49, 52]. The significant decrease of actin gene 
expression at 48 hours compared to 24 hours of infection is consistent with the 
observation that actin levels decrease at later stages of HSV-1 infection [ 52]. 
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The dramatic decrease in expression of the secretase genes seen at 48 hpi may 
reflect general viral-mediated shut down of host gene expression as the virus replicates, 
however the extent of transcriptional down regulation differed among the secretase genes 
and actin. BACEl had the greatest decline in gene expression of the three secretase 
genes. One could speculate that cell signaling pathways regulated by P-secretase 
processing may be affected to a greater extent than those regulated by u-secretases, which 
may perhaps include APP processing. Also, qualitatively we looked at BACEl protein 
levels through immunofluorescence of astrocytes at 24 hpi and observed increased 
BACEl labeling in HSV-1 infected cells relative to uninfected astrocytes. The decrease 
in gene expression for BACEl with HSV-1 infection while observing an increase in 
BACEl protein staining can be due to BACEl half-life being long enough such that the 
gene expression decline at 24 hpi was not yet evident at the protein level. It would be 
interesting to determine how HSV-1 infection affects BACEl protein levels and enzyme 
activity over time, as well as relative levels of ADAMIO versus BACEl generated APP 
fragments. 
4.4 Manipulation of astrocytes gene expression in the presence of Chlamydia 
pneumoniae 
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When comparing Cpn infected and uninfected astrocytes at 24 hpi, there was no 
significant change in ADAMlO, BACEl, PSENl or actin gene expression. This could be 
due to Cpn being in a relatively early part of its life cycle where it is still in the phase of 
converting from EBs into RBs. One could speculate that there isn't a significant change 
in gene expression at 24 hours since Cpn is not fully in its metabolically active form, thus 
not yet affecting host gene expression. 
While ADAMlO, PSENl and actin gene expression did not significantly change 
following a 48 hour infection with Cpn, data indicated a significant increase ofBACEl 
gene expression in infected astrocytes at this time point. These results agree with 
previous lab studies using an MOI of 1, which also included an analysis of protein levels 
and enzymatic activity of BACE 1 at 48 hpi, and demonstrated an increase in both. These 
prior results, along with the observed increase in BACEl gene expression from this 
study, suggest a potential increase in APP processing, eventually leading to an increase of 
amyloid ~ deposits. 
It is interesting to note that while BACEl gene expression was increased at 48 
hpi, expression of neither PSENl nor ADAM!O genes were significantly different than 
uninfected cells at that time point. Perhaps there is an alternate function of BACE 1 that 
promotes the infection ofCpn, thereby favoring enhancement of the expression of that 
enzyme and not ADAM!O orPSENl. It is not known whether the increase in BACEl 
expression observed here is a direct or indirect consequence of Cpn infection. 
4.5 Manipulation of astrocyte gene expression during Chlamydia pneumoniae and 
Herpes simplex virus type 1 coinfections 
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Although infection of astrocytes with HSV-1 alone revealed a decrease in 
expression of all three secretase genes by 24 hours, simultaneous infection with both 
HSV-1 and Cpn for 24 hours (HSV-1/Cpn 24/24 hpi) resulted in no significant change in 
expression of the three secretase genes when compared to uninfected astrocytes. 
Similarly, the decrease in gene expression observed in astrocytes infected with HSV-1 
alone for 48 hours was lessened in the presence of Cpn during simultaneously inoculated 
dual infections (HSV-1/Cpn 48/48 hpi). Once within a host cell, Cpn and HSV-1 would 
have different effects on cellular function to allow their respective infections to progress. 
Viruses such as HSV-1 tend to take over cellular functions and control transcription, 
whereas Cpn replicates within inclusion bodies using cellular energy. Presumably, the 
two pathogens would have different requirements for manipulating cellular functions. 
Our data suggest that Cpn was able to modify virus-induced. changes in gene expression 
to some extent, but not prevent or reverse the HSV-1-induced downregulation of 
expression in the genes we examined. 
The data indicate that expression ofBACEl by Cpn-infected astrocytes at 48 bpi 
increased relative to that seen in 48 hour uninfected cells. However, this increase was 
negated in the presence of HSV-1, even when the virus was added 24 hours after Cpn had 
established infection (HSV-1/Cpn 24/48 bpi). This could reflect an ability ofHSV-1 to 
outcompete Cpn as both pathogens replicate within the same host cell. 
Astrocytes that were first infected with HSV-1 and then inoculated with Cpn at 24 
bpi (HSV-1/Cpn 48/24 hpi) demonstrated similar levels ofsecretase gene expression as 
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seen with HSV-1 alone at 48 hours. By 48 hpi, extensive viral replication had already 
occurred; presumably, when Cpn was added, the bacteria was unable to modify HSV-1-
induced changes in gene expression. OveralL the observation that various levels of gene 
expression differ during dual infection of astrocytes compared to single infections 
demonstrates how HSV-1 and Cpn have an effect on each other. 
4.6 Herpes simplex virus type 1 replication in astrocytes in the presence and absence 
of Chlamydia pneumoniae 
In addition to assessing the effect of single and dual infections of astrocytes on 
secretase gene expression, we also wanted to consider how HSV-1 and Cpn affect each 
other's ability to replicate in dually infected astrocytes. Through immunofluorescence it 
was revealed that both HSV-1 and Cpn can co-habitate a single astrocyte at 24 hpi and 48 
hpi. However, quantitative RT-PCR depicted a competition between the pathogens. At 24 
hpi, when Cpn simultaneously infected astrocytes with HSV-1 (HSV-1/Cpn 24/24 hpi) 
there was a significant drop in HSV-1 copy numbers. This could reflect competition 
between the two pathogens for the same receptor or entry pathway. This competition 
would not occur when HSV-1 was added to astrocytes already infected with Cpn 
(HSV/Cpn 24/48 hpi) since Cpn would already be internalized, which is consistent with 
the data indicating similar copy numbers from HSV-1 24 hour alone infection and 
RSV /Cpn 24/48 hpi samples. It is interesting to note that for coinfected cells at 48 hours 
ofHSV-1 infection (HSV-1/Cpn 48/48 hpi or HSV-1/Cpn 48/24 hpi) there was no 
significant change in copy numbers when compared to 48 hour HSV-1 single infections. 
These data may indicate that Cpn inhibits HSV-1 replication by interfering with an early 
step in viral replication, such as attachment or entry; once viral replication increases 
exponentially, it overcomes any early inhibition by Cpn. 
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If HSV-1 and Cpn were to compete for receptors on host cells it would be 
consistent with the observation that HSV-2 and Chlamydia trachomatis compete for 
binding to nectinl to enable entry into host cells [65]. In addition, Cpn and HSV-1 both 
interact with the epithelial growth factor receptor for entry, therefore it is reasonable to 
conclude that during dual infections, Cpn and HSV-1 could be in direct competition with 
each other to establish infection in host cells [66, 67]. At 24 hpi, ifCpn were to inhibit 
HSV-1 replication, it could explain the impaired inhibition of secretase expression in 
simultaneously inoculated dual infections (HSV/Cpn 24/24 hpi) compared to single HSV-
1 infections. However, HSV-1 copy numbers at 48 hpi were similar regardless of the 
presence or absence ofCpn. Therefore, the diminished shutdown ofHSV-1-induced host 
gene expression observed in 48 hour dual infections (HSV/Cpn 48/48 hpi) cannot be 
explained by inhibition of viral replication in the presence of Cpn. 
4.7 Chlamydia pneumoniae replication in astrocytes in the presence and absence of 
Herpes simplex virus type I 
Unlike the HSV-1 copy numbers, as a Cpn infection goes from 24 hours to 48 
hours Cpn copy numbers decrease. It is possible that this apparent drop in Cpn copy 
numbers is a reflection of the complex life cycle of Cpn. Copy numbers were quantified 
by amplification of cDNA using a primer specific for chlamydia ! 6s rRNA and should, 
therefore, reflect levels of chlamydia! mRNA. Since RBs are the metabolically active 
form of Cpn, higher levels of Cpn mRNA would be expected to be associated with RBs 
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than with a similar number ofEBs. Furthermore, RBs are capable of multiplying, 
suggesting that higher levels of chlamydia! mRNA would be associated with the stage in 
the Cpn life cycle when EBs have largely converted to RBs. At later time points, as RBs 
convert back into EBs, chlamydia! mRNA might be expected to decrease. It is possible 
that in our infections of astrocytes, at 48 hpi RBs have already converted back into EBs, 
or are in the process of doing so, and therefore cDNA-associated copy number could be 
dropping. 
It is also important to consider that the RT2-PCR amplification protocol 
normalized RNA levels between samples using a host l 8s rRNA primer. It is possible 
that astrocyte cell division allowed host cell mRNA to increase at a rate that was more 
rapid than that of Cpn mRNA. This would result in Cpn sequences accounting for a lower 
percentage of total mRNA in cell lysates at 48 hpi than at 24 hpi, which could also 
explain an apparent drop in Cpn copy number at 48 hpi relative to 24 hpi. 
Interestingly, in all dual infections, Cpn copy number was always greater in the 
presence ofHSV-1 than that measured in the appropriate single Cpn infection. It is 
possible that HSV-1 enhances the Cpn life cycle, perhaps by increasing the rate of 
multiplication ofRBs. Alternatively, the virus may somehow prevent the conversion of 
RBs back into EBs, thereby resulting in a greater number of cDNA-associated copy 
numbers. Interestingly, HSV-2 drives Chlamydia trachomatis into persistence [68], 
whereas a similar phenomenon may not occur with HSV-1 and Cpn. 
In addition, it is possible that extraction of RNA from Cpn in its EB form may not 
be as efficient as RNA extraction from Cpn in its RB form. The increase in Cpn copy 
number observed in coinfected cells relative to that of single infections may reflect more 
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efficient extraction of Cpn RNA in host cells whose membranes were altered by infection 
with HSV-1. HSV-1 infection can cause syncytia formation therefore altering the cell 
membrane integrity hence more RNA can be extracted. 
4.8 Future Directions 
Now that there is data showing that there is a change in gene expression in the 
secretases involved in processing APP in the presence ofHSV-1 and/or Cpn, the next 
step would be to see if changes in the protein levels parallel changes in gene expression 
in infected astrocytes. Western blots could be used to assess protein levels of ADAMIO, 
BACEl, and PSENl in single and dual infection ofastrocytes. Although infection of 
astrocytes with HSV-1 decreases the transcription of all three secretases, if these enzymes 
are relatively stable they may still be able to persist and contribute to the neurological 
pathology observed in AD. It would also be interesting to examine earlier time points, 
such as 6 bpi and 12 bpi, since we are predicting that HSV-1 and Cpn compete with each 
other earlier on in infections. 
Using western blots to examine possible changes in AP(l-42) levels in infected 
astrocyte lysates and culture supernatants will help clarify whether AP processing is 
being altered as a result of single or dual infections and whether it is being secreted out of 
the cell. Analysis of the enzymatic activity of ADAMlO, BACEl, and PSENl can also 
be conducted on infected astrocyte lysates and would provide information on changes in 
APP processing as a result of infection. Therefore, we can examine the whole process 
from gene expression to protein to enzymatic activity in order to gain a clearer 
understanding of how A~ is affected by HSV-1 and Cpn infection. 
There are other enzymes and proteins involved in APP processing that could be 
examined to provide a more complete understanding of the role these pathogens play in 
AD pathology. For example, we could address the question of whether HSV-1 or Cpn 
alters clearance of A~ by examining the expression and activity of neprilysin, which 
plays a role in A~ clearance. It is possible that HSV-1 and/or Cpn play a role in AD 
pathology by altering the clearance of A~ as well as the generation of these neurotoxic 
fragments. 
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To investigate further the effect ofHSV-1 and Cpn on each other, we need to 
clarify the occurrence and timing of EBs, RBs or persistent forms the Cpn within infected 
astrocytes in both the presence and absence of HSV-1. Electron microscopy is currently 
the accepted method to identify the different forms of Cpn within a host cell. This 
approach would help clarify how HSV-1 may effect the Cpn biphasic life cycle. 
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